Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with ...
Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...
Pharmabiz6 小时
Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for ...
Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...